POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Hoyland on August 21, 2013, 12:13:29 am
-
The City of Hope is applying to start a new Pl trial of the Sangamo Zinc Finger Nuclease HIV treatment. Here is the agenda item for next month's RAC meeting.
Discussion on Human Gene Transfer Protocol #1307-1240 titled: A
Phase I, Open-Label Study to Assess the Safety, Feasibility and
Engraftment of Zinc Finger Nucleases CCR5 Modified Autologous CD34+
Hematopoietic Stem/Progenitor Cells (Sb-728mr-Hspc) with Escalating
Doses Of Busulfan in HIV-1 (R5) Infected Subjects with Suboptimal CD4
Levels on Antiretroviral Therapy
PIs: Amrita Krishnan, M.D., City of Hope, Duarte, CA
John Zaia, M.D, City of Hope, Duarte, CA
If RAC recommend the trial goes ahead, then I think CoH will have to submit a new IND to the FDA before the trail can commence. It is possible that the trail could begin by the end of the year, if the FDA has no objections.
http://oba.od.nih.gov/oba/RAC/meetings/Sept2013/Sept_11-12_2013_agenda-Public_Draft.pdf (http://oba.od.nih.gov/oba/RAC/meetings/Sept2013/Sept_11-12_2013_agenda-Public_Draft.pdf)
-
This is different. It's stem cells. Previous trials modified T-Cells.
-
This is different. It's stem cells. Previous trials modified T-Cells.
Large.